Experience

Oyster Point Pharma to Be Acquired by Viatris

November 10, 2022

Cooley advised Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, on its definitive agreement to be acquired by global healthcare company Viatris. Partners Mika Reiner Mayer, Brandon Fenn, Div Gupta and Ian Nussbaum led the Cooley team advising Oyster Point Pharma.

Read more

Related contacts

Mika Reiner Mayer
Partner, Palo Alto
Brandon W. Fenn
Partner, New York
Div Gupta
Partner, New York
Sarah Lightdale
Partner, New York
Eileen Marshall
Partner, Washington DC
Howard Morse
Partner, Washington DC
John Paul Oleksiuk
Partner, New York
Nyron J. Persaud
Partner, New York
John Robertson
Partner in Charge – Seattle, Seattle
Charity Williams
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington DC
Ryan Montgomery
Special Counsel, Boston
Thomas Welk
Senior Counsel, San Diego
Nathan Baum
Associate, New York
Kimberly Bolin
Patent Agent, Palo Alto
Julia R. Brinton
Associate, Washington DC
Cara Buchicchio
Associate, New York
Colette Ghazarian
Associate, Los Angeles Downtown
Liz Gold
Associate, New York
Amanda Griggs
Associate, New York
Edward (Teddy) Nimetz
Associate, New York
Ryan Walker
Associate, New York

NerdWallet – $150.1 Million IPO

November 15, 2021

Cooley advised NerdWallet, a personal finance website and app, on its $150.1 million initial public offering of 8,337,500 shares of Class A common stock, which now trade on the Nasdaq Global Market under the symbol NRDS. Lawyers David Peinsipp, John Sellers and Nicole Orders led the Cooley team advising NerdWallet.

Read more

Related contacts

John Sellers
Partner, Palo Alto
David Peinsipp
Partner, San Francisco
Debbie Wilkins
Paralegal Specialist, Palo Alto
Alla Kagan
Paralegal Specialist, San Diego
Alessandra Murata
Partner, Palo Alto
Jeff Goldman
Special Counsel, Palo Alto
Alexander Ellebracht
Associate, Palo Alto
Nicola Squire
Partner, London
Kristopher Kleiner
Special Counsel, Colorado
Kevin King
Partner, Washington DC
Shannon MacMichael
Special Counsel, Washington DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Stephanie Gentile
Partner, New York
Amanda Pacheco
Associate, Palo Alto
Megan Browdie
Partner, Washington DC
Nicollette R. Kirby
Associate, Washington DC
Bryan Berman
Special Counsel, Colorado
Francis Wheeler
Partner, Colorado
Brandon W. Fenn
Partner, New York

Molecular Partners – $64 Million IPO

June 16, 2021

Cooley advised Molecular Partners on its $63.75 million initial public offering of 7,000,000 American depositary shares. Molecular Partners, whose securities now trade on the Nasdaq Global Select Market  under the symbol MOLN, is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics. Partners Div Gupta, Ryan Sansom, Brandon Fenn and John Robertson led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Ryan Sansom
Partner, Boston
Brandon W. Fenn
Partner, New York
John Robertson
Partner in Charge – Seattle, Seattle

VectivBio – $147 Milion IPO

April 9, 2021

Cooley advised VectivBio on its $146.6 million initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters’ option to purchase additional shares. VectivBio, whose securities now trade on the Nasdaq Global Market under the symbol VECT, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Partners Div Gupta, Ryan Sansom and Brandon Fenn led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Ryan Sansom
Partner, Boston
Brandon W. Fenn
Partner, New York

Edgewise Therapeutics – $202 Million IPO

March 25, 2021

Cooley advised the underwriters on Edgewise Therapeutics’ $202.4 million initial public offering of 12,650,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan Securities, Goldman Sachs and SVB Leerink acted as joint book-running managers for the offering. Edgewise Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol EWTX, is a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Partners Richard Segal, Div Gupta, Ryan Sansom and Brandon Fenn led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Ryan Sansom
Partner, Boston
Brandon W. Fenn
Partner, New York
View more